World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
54511
World Ranking
11954
National Ranking
6128

Jonathan E. Rosenberg publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jonathan E. Rosenberg sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 638 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jonathan E. Rosenberg D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan E. Rosenberg sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jonathan E. Rosenberg is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research focuses mainly on medicine, with a strong emphasis on surgery and oncology, alongside contributions to pulmonary and respiratory medicine, molecular biology, and cancer research.

Their primary areas of study include several specialized topics within cancer treatment and research. These topics are:

  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Cancer Immunotherapy and Biomarkers
  • Esophageal Cancer Research and Treatment
  • Renal Cell Carcinoma Treatment
  • Epigenetics and DNA Methylation
  • Fibroblast Growth Factor Research

Jonathan E. Rosenberg has coauthored extensively with several collaborators, including:

  • Dean F. Bajorin
  • Gopa Iyer
  • Hikmat Al-Ahmadie
  • Bernard H. Bochner
  • Samuel A. Funt

Their research has been published frequently in notable scientific journals, with the most frequent venues being:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • European Urology
  • Clinical Cancer Research
  • Annals of Oncology

Significant recent publications authored or coauthored by Jonathan E. Rosenberg include:

  • EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma, 2020, Journal of Clinical Oncology
  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, 2021, New England Journal of Medicine
  • Genomic Characterization of Metastatic Patterns from Prospective Clinical Sequencing of 25,000 Patients, 2022, Cell
  • High Systemic and Tumor-Associated IL-8 Correlates with Reduced Clinical Benefit of PD-L1 Blockade, 2020, Nature Medicine
  • Adjuvant Atezolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial, 2021, The Lancet Oncology

Best Publications

  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

    Sanjeev Mariathasan;Shannon J. Turley;Dorothee Nickles;Alessandra Castiglioni

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Comprehensive molecular characterization of urothelial bladder carcinoma

    John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

    Sam S. Chang;Bernard H. Bochner;Roger Chou;Robert Dreicer

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    Thomas Powles;Jonathan E Rosenberg;Guru P Sonpavde;Yohann Loriot

  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim

  • Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Matthew D. Galsky;Noah M. Hahn;Jonathan Rosenberg;Guru Sonpavde

  • Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

    Eliezer M Van Allen;Kent W. Mouw;Philip Kim;Gopa Iyer

  • Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

    Jonathan E. Rosenberg;Jonathan E. Rosenberg;Peter H. O’Donnell;Arjun V. Balar;Bradley A. McGregor

  • Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Toni K. Choueiri;Ulka Vaishampayan;Jonathan E. Rosenberg;Theodore F. Logan

  • Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials

    Toni K. Choueiri;Fabio A.B. Schutz;Youjin Je;Jonathan E. Rosenberg

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

  • Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

    Joaquim Bellmunt;Toni K. Choueiri;Ronan Fougeray;Fabio A.B. Schutz

  • Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

    Min Yuen Teo;Kenneth Seier;Irina Ostrovnaya;Ashley M. Regazzi

  • Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.

    Jaegil Kim;Kent W Mouw;Kent W Mouw;Paz Polak;Lior Z Braunstein;Lior Z Braunstein

Frequent Co-Authors

Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Bernard H. Bochner
Bernard H. Bochner Memorial Sloan Kettering Cancer Center
Hikmat Al-Ahmadie
Hikmat Al-Ahmadie Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Thomas Powles
Thomas Powles Queen Mary University of London
Guido Dalbagni
Guido Dalbagni Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary pathways to a traditional MD can open doors to a wide range of rewarding healthcare careers. Many students consider online or hybrid degrees that offer flexibility and cost savings while still leading to important positions in the medical and health industry.

If you're interested in leadership or administration, earning an mha degree cost is a crucial factor to consider as you compare program options. For nurses aiming to advance their practice, some of the cheapest bsn to dnp programs provide a streamlined, affordable route from a bachelor's to a doctorate in nursing.

Those pursuing a career in pharmacy can benefit from enrolling in an online pharmd program, which combines flexibility with specialized training. Meanwhile, the demand for professionals skilled in managing clinical data is growing — earning a health information management degree online can set you on a path toward one of healthcare’s fastest-expanding fields.

Whether you’re seeking patient-facing roles, administration, or data-driven positions, exploring these online degree options can help you find an affordable and accessible path to a fulfilling career in healthcare.

Best Scientists Citing Jonathan E. Rosenberg

Trending Scientists

Recently Published Articles